-
2
-
-
0027378724
-
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
-
Wong DK, Cheung AM, O'Rourke K, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23.
-
(1993)
Ann Intern Med
, vol.119
, pp. 312-323
-
-
Wong, D.K.1
Cheung, A.M.2
O'Rourke, K.3
Detsky, A.S.4
Heathcote, J.5
-
3
-
-
8544280731
-
Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan
-
Suzuki F, Arase Y, Akuta N et al. Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol 2004; 39: 969-74.
-
(2004)
J Gastroenterol
, vol.39
, pp. 969-974
-
-
Suzuki, F.1
Arase, Y.2
Akuta, N.3
-
4
-
-
0029591574
-
A preliminary trial of lamivudine for chronic hepatitis B infection
-
Dienstag JL, Perrilo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-61.
-
(1995)
N Engl J Med
, vol.333
, pp. 1657-1661
-
-
Dienstag, J.L.1
Perrilo, R.P.2
Schiff, E.R.3
Bartholomew, M.4
Vicary, C.5
Rubin, M.6
-
5
-
-
0032499913
-
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
-
Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
-
(1998)
N Engl J Med
, vol.339
, pp. 61-68
-
-
Lai, C.L.1
Chien, R.N.2
Leung, N.W.3
-
6
-
-
0033592764
-
Lamivudine as initial treatment for chronic hepatitis B in the United States
-
Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
-
(1999)
N Engl J Med
, vol.341
, pp. 1256-1263
-
-
Dienstag, J.L.1
Schiff, E.R.2
Wright, T.L.3
-
7
-
-
0033067028
-
Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection
-
Suzuki Y, Kumada H, Ikeda K et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743-8.
-
(1999)
J Hepatol
, vol.30
, pp. 743-748
-
-
Suzuki, Y.1
Kumada, H.2
Ikeda, K.3
-
8
-
-
0030875066
-
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
-
Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26: 1393-5.
-
(1997)
J Hepatol
, vol.26
, pp. 1393-1395
-
-
Honkoop, P.1
Niesters, H.G.2
de Man, R.A.3
Osterhaus, A.D.4
Schalm, S.W.5
-
9
-
-
17344373482
-
Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term Lamivudine therapy and re-takeover by wild type after cessation of therapy
-
Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term Lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-16.
-
(1998)
Hepatology
, vol.27
, pp. 1711-1716
-
-
Chayama, K.1
Suzuki, Y.2
Kobayashi, M.3
-
10
-
-
0042743964
-
Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan
-
Suzuki F, Tsubota A, Arase Y et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003; 46: 182-9.
-
(2003)
Intervirology
, vol.46
, pp. 182-189
-
-
Suzuki, F.1
Tsubota, A.2
Arase, Y.3
-
11
-
-
0030872946
-
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
-
Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41: 1444-8.
-
(1997)
Antimicrob Agents Chemother
, vol.41
, pp. 1444-1448
-
-
Innaimo, S.F.1
Seifer, M.2
Bisacchi, G.S.3
Standring, D.N.4
Zahler, R.5
Colonno, R.J.6
-
12
-
-
0035114188
-
The polymerase L528M mutation correlates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
-
Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation correlates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449-55.
-
(2001)
J Clin Invest
, vol.107
, pp. 449-455
-
-
Ono, S.K.1
Kato, N.2
Shiratori, Y.3
-
13
-
-
0034867425
-
Safety and efficacy of oral Entecavir given for 28days in patients with chronic hepatitis B virus infection
-
DeMan RA, Wolters LM, Nevens F et al. Safety and efficacy of oral Entecavir given for 28days in patients with chronic hepatitis B virus infection. Hepatology 2001; 34: 578-82.
-
(2001)
Hepatology
, vol.34
, pp. 578-582
-
-
DeMan, R.A.1
Wolters, L.M.2
Nevens, F.3
-
14
-
-
0036892435
-
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection
-
Lai CL, Rosmawati M, Lao J et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831-8.
-
(2002)
Gastroenterology
, vol.123
, pp. 1831-1838
-
-
Lai, C.L.1
Rosmawati, M.2
Lao, J.3
-
15
-
-
0035890097
-
Long-term Entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection
-
Colonno RJ, Genovesi EV, Medina I et al. Long-term Entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001; 184: 1236-45.
-
(2001)
J Infect Dis
, vol.184
, pp. 1236-1245
-
-
Colonno, R.J.1
Genovesi, E.V.2
Medina, I.3
-
16
-
-
0000349340
-
Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy
-
Tassopoulos N, Hadziyannis S, Cianciara J et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 2001; 34: 340A.
-
(2001)
Hepatology
, vol.34
-
-
Tassopoulos, N.1
Hadziyannis, S.2
Cianciara, J.3
-
17
-
-
26844500312
-
A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients
-
Chang TT, Gish RG, Hadziyannis SJ et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198-209.
-
(2005)
Gastroenterology
, vol.129
, pp. 1198-1209
-
-
Chang, T.T.1
Gish, R.G.2
Hadziyannis, S.J.3
-
18
-
-
2442680071
-
Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR
-
Punia P, Cane P, Teo CG, Saunders N. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J Hepatol 2004; 40: 986-92.
-
(2004)
J Hepatol
, vol.40
, pp. 986-992
-
-
Punia, P.1
Cane, P.2
Teo, C.G.3
Saunders, N.4
-
19
-
-
4344627233
-
Clinical emergence of Entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine
-
Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of Entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-507.
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 3498-3507
-
-
Tenney, D.J.1
Levine, S.M.2
Rose, R.E.3
-
20
-
-
0024427902
-
Mutation preventing formation of e antigen in patients with chronic HBV infection
-
Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet 1989; ii: 588-91.
-
(1989)
Lancet
, vol.2
, pp. 588-591
-
-
Carman, W.F.1
Jacyna, M.R.2
Hadziyannis, S.3
-
21
-
-
0028222146
-
Mutations in pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pregenome encapsidation signal
-
Lok ASF, Akarca US, Greene S. Mutations in pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pregenome encapsidation signal. Proc Natl Acad Sci USA 1994; 91: 4077-81.
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, pp. 4077-4081
-
-
Lok, A.S.F.1
Akarca, U.S.2
Greene, S.3
-
22
-
-
0029817029
-
Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on pre-core gene expression and viral replication
-
Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on pre-core gene expression and viral replication. J Virol 1996; 70: 5845-51.
-
(1996)
J Virol
, vol.70
, pp. 5845-5851
-
-
Buckwold, V.E.1
Xu, Z.2
Chen, M.3
Yen, T.S.4
Ou, J.H.5
-
23
-
-
0033760350
-
Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy
-
Cho SW, Hahm K-B, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32: 1163-9.
-
(2000)
Hepatology
, vol.32
, pp. 1163-1169
-
-
Cho, S.W.1
Hahm, K.-B.2
Kim, J.H.3
-
24
-
-
0036893202
-
Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy
-
Suzuki F, Suzuki Y, Tsubota A et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 2002; 37: 824-30.
-
(2002)
J Hepatol
, vol.37
, pp. 824-830
-
-
Suzuki, F.1
Suzuki, Y.2
Tsubota, A.3
-
25
-
-
33745726960
-
Changes in viral load of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy
-
Suzuki F, Kumada H, Nakamura H. Changes in viral load of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 2006; 78: 1025-34.
-
(2006)
J Med Virol
, vol.78
, pp. 1025-1034
-
-
Suzuki, F.1
Kumada, H.2
Nakamura, H.3
-
26
-
-
0024605518
-
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
-
Newton CR, Graham A, Heptinstall LE et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989; 17: 2503-16.
-
(1989)
Nucleic Acids Res
, vol.17
, pp. 2503-2516
-
-
Newton, C.R.1
Graham, A.2
Heptinstall, L.E.3
-
27
-
-
0029082116
-
A novel method for efficient amplification of whole hepatitis B virus genomes permit rapid functional analysis and reveals deletion mutants in immunosuppressed patients
-
Günther S, Li BC, Miska S, Krüger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permit rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69: 5437-44.
-
(1995)
J Virol
, vol.69
, pp. 5437-5444
-
-
Günther, S.1
Li, B.C.2
Miska, S.3
Krüger, D.H.4
Meisel, H.5
Will, H.6
-
28
-
-
0037235229
-
Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: Emergence of YMDD motif mutant and risk of breakthrough hepatitis - An open-cohort study
-
Akuta N, Tsubota A, Suzuki F et al. Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: Emergence of YMDD motif mutant and risk of breakthrough hepatitis - an open-cohort study. J Hepatol 2003; 38: 91-7.
-
(2003)
J Hepatol
, vol.38
, pp. 91-97
-
-
Akuta, N.1
Tsubota, A.2
Suzuki, F.3
-
29
-
-
0036858638
-
Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy
-
Suzuki F, Tsubota A, Akuta N et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol 2002; 37: 922-7.
-
(2002)
J Gastroenterol
, vol.37
, pp. 922-927
-
-
Suzuki, F.1
Tsubota, A.2
Akuta, N.3
-
30
-
-
0035991863
-
Efficacies of Entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro
-
Levine S, Hernandez D, Yamanaka G etal. Efficacies of Entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46: 2525-32.
-
(2002)
Antimicrob Agents Chemother
, vol.46
, pp. 2525-2532
-
-
Levine, S.1
Hernandez, D.2
Yamanaka, G.3
-
31
-
-
1242337438
-
Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy
-
Werle B, Cinquin K, Marcellin P et al. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J Viral Hepat 2004; 11: 74-83.
-
(2004)
J Viral Hepat
, vol.11
, pp. 74-83
-
-
Werle, B.1
Cinquin, K.2
Marcellin, P.3
|